Release Date: June 4, 2022
Expiration Date: June 29, 2022
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non-small cell lung cancer. In this educational program these experts use a case-based format to discuss best practices associated the first-line treatment selection in patients with EGFR-mutant, metastatic NSCLC, particular in cases with high-risk co-mutations.
This educational activity is an archive of the live presentation held on June 3, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
These activities are intended for oncologists, pathologists and other oncology healthcare professionals interested in the latest advances in the diagnosis, treatment, and management of lung cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the role of multidisciplinary team members in addressing barriers to testing and the interpretation of molecular test results for patients with early stage and metastatic NSCLC
- Summarize high-risk genomic co-mutations that occur in patients with EGFR mutation-positive NSCLC
- Assess outcomes among EGFR mutation profiles with the application of different EGFR inhibitor-based monotherapy and combination regimens
- Apply approaches to mitigate and manage treatment-related toxicities associated with the use of targeted therapy in patients with early-stage and metastatic NSCLC
Edward B. Garon, MD, MS
Professor of Medicine (Hematology/Oncology)
David Geffen School of Medicine at the University of California, Los Angeles
Los Angeles, CA
Disclosures: Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Dynavax Technologies, Eli Lilly, EMD Serono, Genentech, Iovance Biotherapeutics, Merck, Mirati Therapeutics, Neon, Novartis; Consultant: ABL-Bio, Boehringer-Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, EMD Serono, Eisai, GlaxoSmithKline, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio.
Lyudmila Bazhenova, MD
Clinical Professor of Medicine
Director, Hematology Oncology Training Program
Lung Cancer Team Leader
Moores Cancer Center
UC San Diego Health
La Jolla, CA
Disclosures: Grant/Research Support: To institution: BeyondSpring; Consultant: Janssen, Novartis, Daichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Merck, NEUVOGEN, ORIC; Shareholder: Epic Sciences.
Solange Peters, MD, PhD
Professor of Medicine
Chair, Thoracic Malignancies
Head, Medical Oncology
Oncology Department
Lausanne University Hospital
Lausanne, Switzerland
Disclosures: Grant/Research Support: Institutional financial support for clinical trials: Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co, Roche/Genentech; Consultant: Consultation/Advisory role: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GlaxoSmithKline, Illumina, Imedex, IQVIA, Incyte, iTeos, Janssen, Medscape, Merck & Co, Merck Serono, Merrimack, Novartis, Novocure, Pharma Mar, Phosplatin Therapeutics, Pfizer, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, SeaGen, Takeda. Speaker: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda.
Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA
Disclosures: Grant/Research Support: AstraZeneca, Novartis, Spectrum, Takeda, Cullinan Oncology, Daiichi Sankyo, AbbVie, Janssen, Tesaro/GlaxoSmithKline; Consultant: Daiichi Sankyo, C4 Therapeutics, Cullinan, Takeda, Janssen, Blueprint, Jazz.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
